Page 2 - Diabetes Drug
Coronavirus scare: India may soon run short of antibiotics, diabetes drugs
Pharmaceutical firms seek nod to produce raw material locally
 "Coronavirus scare: India may soon run short of antibiotics, diabetes drugs")
Sweet shake-up: Price relief for diabetes patients as drugs go off patent
The Rs 14,000-crore diabetes drug market in the country is witnessing a churn
 "Sweet shake-up: Price relief for diabetes patients as drugs go off patent")
Is it possible to keep diabetes under check? Here are a few ways to manage
The most important thing for diabetic patients is to keep their blood sugar level under control to avoid hospitalization
 "Is it possible to keep diabetes under check? Here are a few ways to manage")
Cipla acquires brand, trademark for anti-diabetic drug Vysov in India
Homegrown pharma major Cipla Ltd on Monday said it has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for the Indian market from Novartis. However, it didn't disclose the acquisition amount. Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing. "Owing to the increased affordability of Vildagliptin it is more accessible for better management of the disease. Cipla's acquisition of the trademark rights of Vysov will enable us to contribute to easier access of the drug in India," Cipla Executive Vice-President & Head India Business Nikhil Chopra said. The products have witnessed a strong uptake in India for the last couple of years and are currently available across the country, the company said. Vildagliptin is backed by strong clinical data and is therefore a widely prescribed antidiabetic medicine for adults with type-2 ..
 "Cipla acquires brand, trademark for anti-diabetic drug Vysov in India")
French watchdog, pharma firm on trial as Diabetes pill causes 500 deaths
Legal experts have concluded the drug may cause as many as 2,100 deaths in the long term
 "French watchdog, pharma firm on trial as Diabetes pill causes 500 deaths")
Glenmark, Torrent Pharma sign agreement to co-market diabetes drug in India
Glenmark launched Remogliflozin, indicated in the treatment of Type 2 Diabetes Mellitus in adults under the brand names Remo and Remozen
 "Glenmark, Torrent Pharma sign agreement to co-market diabetes drug in India")
New diabetes drug could replace painful insulin jabs
Partial activation can have the benefit of fewer side-effects than full activation
